IN THE STUDY Sample Clauses

IN THE STUDY. This consent form contains important information to help you decide if you want to be in the study. If you have any questions that are not answered in this consent form, ask one of the study staff. Please answer YES or NO to the following questions:
AutoNDA by SimpleDocs
IN THE STUDY. While on the study, the risks are: • Loss of Confidentiality: Every precaution will be taken to remove identifying information from all data taken for this study, but absolute assurance of confidentiality cannot be given.
IN THE STUDY. Part 1 (Cohorts 1-6) Payment If in Part 1, you may receive up to $3300.00 for being in the study. You will be paid per completed visit as follows: You will receive two separate payments within 10 business days from Day 14 and Day 30. Visit Payment (amount) Screening $0.00 Day -1 $200.00 Day 1 $250.00 Day 2 $250.00 Day 3 $250.00 Day 4 $250.00 Day 5 $250.00 Day 6 $250.00 Day 7 $250.00 Day 14 $150.00 Day 21 $25.00 Day 30 $200.00 Bonus $975.00 *Total Payment* $3,300.00 To ensure that each dosing group reaches the maximum number of subjects, extra subjects will be recruited. All participants will be asked to complete research study procedures up to the time of dosing. In the event that a study subject is unable to dose, another qualified subject will take that subject’s place on the study. If you complete all the requirements, but are not dosed, you will receive a pro-rated stipend check based on information below. If you not selected to be in the study, you will be paid $200.00 if you are released on day -1 and $400.00 if released on day 1. As an alternate, you may be asked to participate in the next dosing group, which may require you to repeat Day -1 and Day 1 procedures. Part 2 (Cohorts 7, 8, 9, and 10) Payment If in Part 2, you may receive up to $6,400.00 for being in the study. You will be paid per completed visit as follows: You will receive two separate payments within 10 business days from Day 21 and Day 45. Visit Payment (amount) Screening $0.00 Day -1 $200.00 Day 1 $250.00 Day 2 $250.00 Day 3 $250.00 Day 4 $250.00 Day 5 $250.00 Day 6 $250.00 Day 7 $250.00 Day 8 $250.00 Day 9 $250.00 Day 10 $250.00 Day 11 $250.00 Day 12 $250.00 Day 13 $250.00 Day 14 $250.00 Day 15 $250.00 Day 16 $250.00 Day 17 $250.00 Day 18 $250.00 Day 19 $250.00 Day 20 $250.00 Day 21 $250.00 Day 30 $175.00 Day 45 $175.00 Bonus $600.00 *Total Payment* $6,400.00 To ensure that each dosing group reaches the maximum number of subjects, extra subjects will be recruited. All participants will be asked to complete research study procedures up to the time of dosing. In the event that a study subject is unable to dose, another qualified subject will take that subject’s place on the study. If you complete all the requirements, but are not dosed, you will receive a pro-rated stipend check based on information below. If you are not selected to be in the study, you will be paid $200.00 if you are released on day -1 and $400.00 if released on day 1. As an alternate, you may be asked to participat...
IN THE STUDY. The overall experience of the xxx.xx app enables users to earn points through their actions in the app. Points will be collected on an ongoing basis by the participant within the app. Cumulative points for this study will be 25,000 points (collected after the participant completes all study required procedures, including the final survey). Participants in this study who complete all the actions can convert these total 25,000 points to a one-time only Xxxxxx.xxx gift card of up to $250.00 in value through the link provided after the final survey. You will be offered a phone stand approximately $10 in value, if you need it. If you are invited to do the usability interview and complete the interview successfully, you will receive a one-time link for a total of $50, redeemable as a one-time Xxxxxx.xxx gift card. The principal investigator is an employee of xxx.xx on whose app this study is being conducted and is being paid by the sponsor to conduct this research study.
IN THE STUDY. You might feel tired from the eye exams or study procedures. Also, the eye exams and measurements may pose risks because some devices come very close to or touch your eyes. There is a small chance that the instrument used could scratch the surface of your eye. If that occurs, it is usually minor. Also, you may experience blurred vision or discomfort from the numbing drop that the study doctor gives you. These could last up to 24 hours after the exam. Also, there is a risk of allergic reaction (itching, redness, burning, or mucous discharge) to the ingredients in the anesthetic (numbing) eye drop used in these evaluations. If experienced, this could last up to 12 hours. Because your eyes are numb, it’s important that you do not rub your eyes for at least 20 minutes after the exam. The orange-yellow (Fluorescein) dye that will be put in your eyes to evaluate the intraocular pressure (pressure inside your eye) may make your skin and bodily secretions and excretions, such as your tears or mucous, change color, or they may cause some irritation to your eyes. This effect is usually temporary and disappears within a day. Rarely, people can have an allergic reaction to fluorescein dye. This would usually involve itching, swelling, or redness. If you develop such a reaction, you will receive treatment. As with any allergy, more serious or life threatening reactions are possible. No adverse reactions (bad side effects) have been reported for the Canon HS100 OCT or Optovue RTVue XR devices. Because the Canon HS100 OCT device is investigational (not yet FDA-approved), all of its side effects may not be known. There may be rare and unknown side effects. You must tell the study doctor and staff if you experience any side effects. If you are not honest about your side effects, it may not be safe for you to be in the study.

Related to IN THE STUDY

  • The Study 2.1The parties must comply with, and conduct the Study in accordance with, the Protocol and any conditions of the Reviewing HREC. In addition the parties must comply with the following, as applicable:

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Field Trips Orange COUNTY funds may not be used to support any overnight and/or out of Central Florida travel, unless approved by the COUNTY’S Manager of the CCC or designee in advance. The AGENCY must have on file for field trip(s) that each participant, adult or minor, must have a signed release of liability form releasing the COUNTY from any liability. If the participant is a minor, the release must be signed by a parent/guardian. Central Florida is defined as Orange, Osceola, Seminole, Brevard, Lake, Polk, and Volusia Counties.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Field The term “

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research Project 3.1 These Materials and Data will be used by Recipient's PI solely in connection with the Research Project, as named and described in the attached research application (insert Research Project name below):

Time is Money Join Law Insider Premium to draft better contracts faster.